Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | STING1 | Q86WV6 | 15/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23635901 | 0.89 | STING1 (0.71) | HSD17B10STING1MKNK1MKNK2IKBKB | |
| SCHEMBL23635881 | 0.84 | STING1 (0.80) | HSD17B10STING1 | |
| SCHEMBL23112089 | 0.79 | STING1 (0.71) | HSD17B10STING1MAPTNPSR1 | |
| SCHEMBL30697663 | 0.79 | STING1 (0.64) | HSD17B10STING1MAPTNPSR1 | |
| SCHEMBL23635868 | 0.79 | STING1 (0.64) | HSD17B10STING1MAPTNPSR1 | |
| SCHEMBL23112028 | 0.78 | STING1 (0.79) | HSD17B10STING1MAPTNPSR1 | |
| SCHEMBL23112016 | 0.77 | STING1 (0.68) | HSD17B10STING1 | |
| SCHEMBL23112230 | 0.77 | HSD17B10 (0.73) | HSD17B10FGFR1MAPTNPSR1 | |
| SCHEMBL30765149 | 0.77 | HSD17B10 (0.73) | HSD17B10FGFR1MAPTNPSR1 | |
| SCHEMBL25851296 | 0.76 | STING1 (0.61) | STING1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD. (AU) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | HSD17B10 4085/4885STING1 1/4885MKNK1 3383/4885 |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | HSD17B10 4151/4885STING1 1/4885MKNK1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.